Conference Day One
Tuesday June 17, 2025

8:25 am Chair’s Opening Remarks

Pursuing the Potential of the Dark Genome to Unlock a New Target Realm

8:30 am Pioneers’ Panel: Shedding a Light on the Value of the Dark Genome to Raise Awareness & Educate the Wider Community

Synopsis

  • Highlighting the vast potential of the dark genome across a range of disease indications to grow appreciation for targeted therapeutics
  • Discussing common investor concerns and how to address these to promote funding in the field
  • How can we demonstrate proof of concept and improved standard of care for dark genome therapeutics?

9:15 am Beyond the Known Genome: Nonexomics’ Dark Genome Breakthroughs in Cancer & Psychiatric Medicine

Synopsis

  • Dark genome’s evolution: from scientific skepticism to therapeutic promise; key paradigm shifts that revealed the dark genome’s disease-driving potential
  • NonExomics’ breakthrough platform for dark genome analysis and target discovery to unlock critical insights in cancer and psychiatric conditions
  • From discovery to impact: targets in oncology and psychiatric disorders, along with a vision for dark genome therapeutics across diseases

Approaching Unknown Territory: Pursuing Efficient Discovery & Prediction of Robust Target Elements Within the Dark Genome

9:45 am Drugging the Dark Genome: Targeting Non-Coding Regulatory RNAs to Treat Human Disease

  • Dan Tardiff Vice President, Head of Discovery, CAMP4 Therapeutics

Synopsis

  • Understanding the biology of regulatory RNAs as essential regulators of gene expression
  • Applying next-generation sequencing and machine learning tools to map RegRNAs and the cell-specific genes they control
  • Discovery of ASOs that target RegRNAs to upregulate gene expression for the potential treatment of metabolic and CNS disorders

10:15 am Morning Refreshments & Speed Networking

11:15 am Leveraging an In Silico Computational Discovery Platform to Identify Disease Specific LncRNAs

  • Hong Liu Vice President & Head of Computational Biology, NextRNA

Synopsis

  • Analyzing integrated multiomics and clinical data to generate high priority targets
  • Challenges in LncRNA target discovery

11:45 am Interrogating the Regulatory Genome to Identify Genetically Validated Drug Targets

Synopsis

  • Mapping genome-wide patterns to uncover a link between genetic mechanisms and disease
  • Screening large-scale datasets to identify and validate existing druggable targets
  • Validating targets with therapeutic potential and stratifying patients by molecular characteristics

12:15 pm Fireside Chat Discussion: Reviewing Comprehensive Methods to Identify Relevant Sections of the Dark Genome to Uncover Novel Targets

Synopsis

  • Discussing optimal methods to combine technologies to gain a holistic overview of the dark genome and determine best practice to uncover targets
  • Reviewing our understanding mechanisms of dark genome regulation to inform future target prediction across DNA, RNA and protein levels
  • Evaluating how disease indication can impact discovery strategy and methods
  • Outlining factors to consider in target discovery including long repeats, aberrant splicing, and epigenomics to influence screening methods

1:00 pm Lunch & Networking

Forming the Optimal Drug Development Strategy to Maximize Targeting Efficacy

2:00 pm Building Optimal Vaccines to Treat Oncology & Infectious Diseases Using the AI-Immunology™ Platform

Synopsis

  • Leveraging an AI platform for fast and efficient target discovery, antigen selection and validation
  • Utilizing flexible functional tools to screen for expression and influence vaccine design
  • Demonstrating efficacy and safety in animal models and clinical trials

2:30 pm Equipping Efficient Target Selection to Spearhead Favorable Efficacies

Synopsis

  • Determining beneficial target properties to predict effective target profiles
  • Considering your drug modality and delivery method and how this may impact targeting ability
  • Comparing potential functional efficacy to prioritize beneficial targets among large numbers of potential targets

3:00 pm Round Table: Evaluating Methodologies to Select a Target Disease Indication

  • Shan Mandy Jiang Senior Scientific Lead, Discovery Bioinformatics, Lilly Oncology, Eli Lilly & Co.

Synopsis

  • The chicken or the egg? Discussing whether to start with the target or indication to inform discovery strategy
  • Determining best practice to screen and identify indications where target is observed with minimal off-target expression
  • Reviewing economic burden and competition to highlight profitability, investment prospects and improvement on current standard of care

3:45 pm Visual Biology Approach to Target & Drug Discovery

Synopsis

  • Reimagining target and drug discovery with the Lightning.AI TechBio platform
  • Utilizing Pathway Light™ to image hundreds of cellular pathways in healthy and diseased cells to generate new, large-scale data for the biology of disease
  • Identifying and analyzing dysregulated pathways of disease to identify novel targets and optimize small molecules to modulate mRNA biology

4:00 pm Close of Conference Day One